Present at LD Micro

Washington, DC USA – June 1, 2018 – Avant Diagnostics, Inc. (OTC Pink: AVDX)
(the “Company,” or AVDX), a healthcare data generating technology company that
specializes in biomarker tests that are being planned or developed in multiple areas of
oncology, today announced that its new President & CEO, Mick Ruxin, M.D., will be
presenting a corporate overview at the 8th Annual LD Micro Invitational on June 5th,
2018 at 2:00pm PT. Management will be available to meet with interested parties for
one-on-one meetings throughout the event.

Presentation Details

Event: 8th Annual LD Micro Invitation
Date: Tuesday, June 5, 2018
Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
Location: Luxe Sunset Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049

About Avant Diagnostics, Inc.
Avant Diagnostics, Inc. (Avant) is a healthcare data generating technology company
that specializes in biomarker tests that are being planned or developed in multiple areas
of oncology. Avant provides personalized medicine data through its TheraLink®
assays, initially for breast cancer, to assist clinical oncologists in identifying likely
responders, for over 70 FDA-approved drug treatment regimens. Avant is the leading
developer of phospho-proteomic technologies for measuring the activation status of key
signaling pathways, with applications across multiple cancer types, including breast,
colorectal and pancreatic, that are instrumental in the development of companion
diagnostics for molecular-targeted therapies. Theralink®, was developed to empower
community physicians and clinical trial investigators with actionable information to make
time sensitive treatment decisions for their patients. Theralink® was designed to inform
physicians which treatments are likely to be effective for their patients at any given
moment in time, and also identify which treatments are unlikely to be effective. This
information has the potential to improve treatment efficacy and reduce side effects by
foregoing ineffective therapy.

Avant Diagnostics’ Pharma Services Business will help drug companies accelerate their
drug discovery programs and facilitate development of companion diagnostics. Avant’s
data generating technologies will also:

•Stratify subjects entering clinical trials (reduces trial costs with smaller cohorts)
•Monitor on and off target drug effects (regulatory filings)
•Quantify phosphoproteome to identify activation of resistance or compensatory
pathways post-treatment
•Evaluate potential proteomic markers for combination therapies
•Repurpose existing therapies for new indications (off-patent drugs and market

For further information please visit
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements may be identified by
the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated”
and “intend,” among others. These forward-looking statements are based on Avant’s
current expectations and actual results could differ materially. There are a number of
factors that could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to, substantial
competition; our ability to continue as a going concern; our need for additional financing;
uncertainties with respect to lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results; and risks related to failure
to obtain FDA clearances or approvals and noncompliance with FDA regulations. There
are no guarantees that any of our products will receive regulatory approval for any
indication or prove to be commercially successful. Avant does not undertake an
obligation to update or revise any forward-looking statement except as required by law.
Investors should read the risk factors set forth in Avant’s Form 10-K filed with the
Securities and Exchange Commission on January 13, 2016, and other periodic reports
filed with the Securities and Exchange Commission.

Avant Investor Relations:
Scott VanderMeer
Interim CFO
Office: 708-710-9200

Source: Avant Diagnostics, Inc.